Top

Published in:

Open Access 01-12-2021 | Review

The recruitment mechanisms and potential therapeutic targets of podocytes from parietal epithelial cells

Authors: Lihua Ni, Cheng Yuan, Xiaoyan Wu

Published in: Journal of Translational Medicine | Issue 1/2021

Abstract

Podocytes are differentiated postmitotic cells which cannot be replaced after podocyte injury. The mechanism of podocyte repopulation after injury has aroused wide concern. Parietal epithelial cells (PECs) are heterogeneous and only a specific subpopulation of PECs has the capacity to replace podocytes. Major progress has been achieved in recent years regarding the role and function of a subset of PECs which could transdifferentiate toward podocytes. Additionally, several factors, such as Notch, Wnt/ß-catenin, Wilms’ tumor-1, miR-193a and growth arrest-specific protein 1, have been shown to be involved in these processes. Finally, PECs serve as a potential therapeutic target in the conditions of podocyte loss. In this review, we discuss the latest observations and concepts about the recruitment of podocytes from PECs in glomerular diseases as well as newly identified mechanisms and the most recent treatments for this process.

Reiser J, Altintas MM. Podocytes. F1000Res. 2016. https://doi.org/10.12688/f1000research.7255.1.CrossRefPubMedPubMedCentral

Endlich N, Siegerist F, Endlich K. Are podocytes motile? Pflugers Arch. 2017;469(7–8):951–7. https://doi.org/10.1007/s00424-017-2016-9.CrossRefPubMed

Endlich K, Kliewe F, Endlich N. Stressed podocytes-mechanical forces, sensors, signaling and response. Pflugers Arch. 2017;469(7–8):937–49. https://doi.org/10.1007/s00424-017-2025-8.CrossRefPubMed

Campbell KN, Tumlin JA. Protecting podocytes: a key target for therapy of focal segmental glomerulosclerosis. Am J Nephrol. 2018;47(1):14–29. https://doi.org/10.1159/000481634.CrossRefPubMed

Smeets B, Moeller MJ. Parietal epithelial cells and podocytes in glomerular diseases. Semin Nephrol. 2012;32(4):357–67. https://doi.org/10.1016/j.semnephrol.2012.06.007.CrossRefPubMed

Sagrinati C, Netti GS, Mazzinghi B, et al. Isolation and characterization of multipotent progenitor cells from the Bowman’s capsule of adult human kidneys. J Am Soc Nephrol. 2006;17(9):2443–56. https://doi.org/10.1681/asn.2006010089.CrossRefPubMed

Romagnani P. Parietal epithelial cells: their role in health and disease. Contrib Nephrol. 2011;169:23–36. https://doi.org/10.1159/000313943.CrossRefPubMed

Ronconi E, Sagrinati C, Angelotti ML, et al. Regeneration of glomerular podocytes by human renal progenitors. J Am Soc Nephrol. 2009;20(2):322–32. https://doi.org/10.1681/asn.2008070709.CrossRefPubMedPubMedCentral

Su H, Chen S, He FF, Wang YM, Bondzie P, Zhang C. New insights into glomerular parietal epithelial cell activation and its signaling pathways in glomerular diseases. Biomed Res Int. 2015;2015: 318935. https://doi.org/10.1155/2015/318935.CrossRefPubMedPubMedCentral

10.

Pippin JW, Kaverina NV, Eng DG, et al. Cells of renin lineage are adult pluripotent progenitors in experimental glomerular disease. Am J Physiol Renal Physiol. 2015;309(4):F341-358. https://doi.org/10.1152/ajprenal.00438.2014.CrossRefPubMedPubMedCentral

11.

Puelles VG, Cullen-McEwen LA, Taylor GE, et al. Human podocyte depletion in association with older age and hypertension. Am J Physiol Renal Physiol. 2016;310(7):F656-f668. https://doi.org/10.1152/ajprenal.00497.2015.CrossRefPubMed

12.

Gupta S, Verfaillie C, Chmielewski D, et al. Isolation and characterization of kidney-derived stem cells. J Am Soc Nephrol. 2006;17(11):3028–40. https://doi.org/10.1681/asn.2006030275.CrossRefPubMed

13.

Ohse T, Vaughan MR, Kopp JB, et al. De novo expression of podocyte proteins in parietal epithelial cells during experimental glomerular disease. Am J Physiol Renal Physiol. 2010;298(3):F702-711. https://doi.org/10.1152/ajprenal.00428.2009.CrossRefPubMed

14.

Zhang J, Hansen KM, Pippin JW, et al. De novo expression of podocyte proteins in parietal epithelial cells in experimental aging nephropathy. Am J Physiol Renal Physiol. 2012;302(5):F571-580. https://doi.org/10.1152/ajprenal.00516.2011.CrossRefPubMed

15.

Zhang J, Pippin JW, Krofft RD, Naito S, Liu ZH, Shankland SJ. Podocyte repopulation by renal progenitor cells following glucocorticoids treatment in experimental FSGS. Am J Physiol Renal Physiol. 2013;304(11):F1375-1389. https://doi.org/10.1152/ajprenal.00020.2013.CrossRefPubMedPubMedCentral

16.

Zhang J, Pippin JW, Vaughan MR, et al. Retinoids augment the expression of podocyte proteins by glomerular parietal epithelial cells in experimental glomerular disease. Nephron Exp Nephrol. 2012;121(1–2):e23-37. https://doi.org/10.1159/000342808.CrossRefPubMed

17.

Smeets B, Uhlig S, Fuss A, et al. Tracing the origin of glomerular extracapillary lesions from parietal epithelial cells. J Am Soc Nephrol. 2009;20(12):2604–15. https://doi.org/10.1681/asn.2009010122.CrossRefPubMedPubMedCentral

18.

Smeets B, Angelotti ML, Rizzo P, et al. Renal progenitor cells contribute to hyperplastic lesions of podocytopathies and crescentic glomerulonephritis. J Am Soc Nephrol. 2009;20(12):2593–603. https://doi.org/10.1681/asn.2009020132.CrossRefPubMedPubMedCentral

19.

Smeets B, Kuppe C, Sicking EM, et al. Parietal epithelial cells participate in the formation of sclerotic lesions in focal segmental glomerulosclerosis. J Am Soc Nephrol. 2011;22(7):1262–74. https://doi.org/10.1681/asn.2010090970.CrossRefPubMedPubMedCentral

20.

Smeets B, Stucker F, Wetzels J, et al. Detection of activated parietal epithelial cells on the glomerular tuft distinguishes early focal segmental glomerulosclerosis from minimal change disease. Am J Pathol. 2014;184(12):3239–48. https://doi.org/10.1016/j.ajpath.2014.08.007.CrossRefPubMedPubMedCentral

21.

Shankland SJ, Anders HJ, Romagnani P. Glomerular parietal epithelial cells in kidney physiology, pathology, and repair. Curr Opin Nephrol Hypertens. 2013;22(3):302–9. https://doi.org/10.1097/MNH.0b013e32835fefd4.CrossRefPubMed

22.

Eng DG, Sunseri MW, Kaverina NV, Roeder SS, Pippin JW, Shankland SJ. Glomerular parietal epithelial cells contribute to adult podocyte regeneration in experimental focal segmental glomerulosclerosis. Kidney Int. 2015;88(5):999–1012. https://doi.org/10.1038/ki.2015.152.CrossRefPubMedPubMedCentral

23.

Lim BJ, Yang JW, Do WS, Fogo AB. Pathogenesis of focal segmental glomerulosclerosis. J Pathol Transl Med. 2016;50(6):405–10. https://doi.org/10.4132/jptm.2016.09.21.CrossRefPubMedPubMedCentral

24.

Chan GC, Eng DG, Miner JH, et al. Differential expression of parietal epithelial cell and podocyte extracellular matrix proteins in focal segmental glomerulosclerosis and diabetic nephropathy. Am J Physiol Renal Physiol. 2019;317(6):F1680-f1694. https://doi.org/10.1152/ajprenal.00266.2019.CrossRefPubMedPubMedCentral

25.

Appel D, Kershaw DB, Smeets B, et al. Recruitment of podocytes from glomerular parietal epithelial cells. J Am Soc Nephrol. 2009;20(2):333–43. https://doi.org/10.1681/asn.2008070795.CrossRefPubMedPubMedCentral

26.

Wanner N, Hartleben B, Herbach N, et al. Unraveling the role of podocyte turnover in glomerular aging and injury. J Am Soc Nephrol. 2014;25(4):707–16. https://doi.org/10.1681/asn.2013050452.CrossRefPubMedPubMedCentral

27.

Schneider RR, Eng DG, Kutz JN, Sweetwyne MT, Pippin JW, Shankland SJ. Compound effects of aging and experimental FSGS on glomerular epithelial cells. Aging. 2017;9(2):524–46. https://doi.org/10.18632/aging.101176.CrossRefPubMedPubMedCentral

28.

Kietzmann L, Guhr SS, Meyer TN, et al. MicroRNA-193a regulates the transdifferentiation of human parietal epithelial cells toward a podocyte phenotype. J Am Soc Nephrol. 2015;26(6):1389–401. https://doi.org/10.1681/asn.2014020190.CrossRefPubMed

29.

Merchant ML, Barati MT, Caster DJ. Proteomic analysis identifies distinct glomerular extracellular matrix in collapsing focal segmental glomerulosclerosis. J Am Soc Nephrol. 2020;31(8):1883–904. https://doi.org/10.1681/asn.2019070696.CrossRefPubMedPubMedCentral

30.

McNicholas BA, Eng DG, Lichtnekert J, Rabinowitz PS, Pippin JW, Shankland SJ. Reducing mTOR augments parietal epithelial cell density in a model of acute podocyte depletion and in aged kidneys. Am J Physiol Renal Physiol. 2016;311(3):F626-639. https://doi.org/10.1152/ajprenal.00196.2016.CrossRefPubMedPubMedCentral

31.

Kim S, Kim YH, Choi KH, Jeong HJ. Glomerular epithelial CD44 expression and segmental sclerosis in IgA nephropathy. Clin Exp Nephrol. 2016;20(6):871–7. https://doi.org/10.1007/s10157-015-1222-z.CrossRefPubMed

32.

Fatima H, Moeller MJ, Smeets B, et al. Parietal epithelial cell activation marker in early recurrence of FSGS in the transplant. Clin J Am Soc Nephrol. 2012;7(11):1852–8. https://doi.org/10.2215/cjn.10571011.CrossRefPubMedPubMedCentral

33.

Pichaiwong W, Hudkins KL, Wietecha T, et al. Reversibility of structural and functional damage in a model of advanced diabetic nephropathy. J Am Soc Nephrol. 2013;24(7):1088–102. https://doi.org/10.1681/asn.2012050445.CrossRefPubMedPubMedCentral

34.

Andeen NK, Nguyen TQ, Steegh F, Hudkins KL, Najafian B, Alpers CE. The phenotypes of podocytes and parietal epithelial cells may overlap in diabetic nephropathy. Kidney Int. 2015;88(5):1099–107. https://doi.org/10.1038/ki.2015.273.CrossRefPubMedPubMedCentral

35.

Xu Z, Fan J. Islet transplantation promotes podocyte regeneration in a model of diabetic nephropathy. Turkish J Med Sci. 2017;47(6):1925–30. https://doi.org/10.3906/sag-1704-102.CrossRef

36.

Migliorini A, Angelotti ML, Mulay SR, et al. The antiviral cytokines IFN-α and IFN-β modulate parietal epithelial cells and promote podocyte loss: implications for IFN toxicity, viral glomerulonephritis, and glomerular regeneration. Am J Pathol. 2013;183(2):431–40. https://doi.org/10.1016/j.ajpath.2013.04.017.CrossRefPubMed

37.

Benigni A, Morigi M, Rizzo P, et al. Inhibiting angiotensin-converting enzyme promotes renal repair by limiting progenitor cell proliferation and restoring the glomerular architecture. Am J Pathol. 2011;179(2):628–38. https://doi.org/10.1016/j.ajpath.2011.04.003.CrossRefPubMedPubMedCentral

38.

Darisipudi MN, Kulkarni OP, Sayyed SG, et al. Dual blockade of the homeostatic chemokine CXCL12 and the proinflammatory chemokine CCL2 has additive protective effects on diabetic kidney disease. Am J Pathol. 2011;179(1):116–24. https://doi.org/10.1016/j.ajpath.2011.03.004.CrossRefPubMedPubMedCentral

39.

Guhr SS, Sachs M, Wegner A, et al. The expression of podocyte-specific proteins in parietal epithelial cells is regulated by protein degradation. Kidney Int. 2013;84(3):532–44. https://doi.org/10.1038/ki.2013.115.CrossRefPubMed

40.

Kaverina NV, Eng DG, Miner JH, Pippin JW, Shankland SJ. Parietal epithelial cell differentiation to a podocyte fate in the aged mouse kidney. Aging. 2020;12(17):17601–24. https://doi.org/10.18632/aging.103788.CrossRefPubMedPubMedCentral

41.

Roeder SS, Stefanska A, Eng DG, et al. Changes in glomerular parietal epithelial cells in mouse kidneys with advanced age. Am J Physiol Renal Physiol. 2015;309(2):F164-178. https://doi.org/10.1152/ajprenal.00144.2015.CrossRefPubMedPubMedCentral

42.

Siebel C, Lendahl U. Notch signaling in development, tissue homeostasis, and disease. Physiol Rev. 2017;97(4):1235–94. https://doi.org/10.1152/physrev.00005.2017.CrossRefPubMed

43.

Hori K, Sen A, Artavanis-Tsakonas S. Notch signaling at a glance. J Cell Sci. 2013;126(Pt 10):2135–40. https://doi.org/10.1242/jcs.127308.CrossRefPubMedPubMedCentral

44.

Mukherjee M, Fogarty E, Janga M, Surendran K. Notch signaling in kidney development, maintenance, and disease. Biomolecules. 2019. https://doi.org/10.3390/biom9110692.CrossRefPubMedPubMedCentral

45.

Ueno T, Kobayashi N, Nakayama M, et al. Aberrant Notch1-dependent effects on glomerular parietal epithelial cells promotes collapsing focal segmental glomerulosclerosis with progressive podocyte loss. Kidney Int. 2013;83(6):1065–75. https://doi.org/10.1038/ki.2013.48.CrossRefPubMedPubMedCentral

46.

Sweetwyne MT, Susztak K. For better or worse: a niche for Notch in parietal epithelial cell activation. Kidney Int. 2013;83(6):988–90. https://doi.org/10.1038/ki.2013.66.CrossRefPubMedPubMedCentral

47.

Merkel CE, Karner CM, Carroll TJ. Molecular regulation of kidney development: is the answer blowing in the Wnt? Pediatr Nephrol. 2007;22(11):1825–38. https://doi.org/10.1007/s00467-007-0504-4.CrossRefPubMedPubMedCentral

48.

Lin Y, Liu A, Zhang S, et al. Induction of ureter branching as a response to Wnt-2b signaling during early kidney organogenesis. Dev Dyn. 2001;222(1):26–39. https://doi.org/10.1002/dvdy.1164.CrossRefPubMed

49.

Kato H, Susztak K. Repair problems in podocytes: Wnt, Notch, and glomerulosclerosis. Semin Nephrol. 2012;32(4):350–6. https://doi.org/10.1016/j.semnephrol.2012.06.006.CrossRefPubMedPubMedCentral

50.

Kato H, Gruenwald A, Suh JH, et al. Wnt/β-catenin pathway in podocytes integrates cell adhesion, differentiation, and survival. J Biol Chem. 2011;286(29):26003–15. https://doi.org/10.1074/jbc.M111.223164.CrossRefPubMedPubMedCentral

51.

Zhou H, Kajiyama H, Tsuji T, et al. Urinary exosomal Wilms’ tumor-1 as a potential biomarker for podocyte injury. Am J Physiol Renal Physiol. 2013;305(4):F553-559. https://doi.org/10.1152/ajprenal.00056.2013.CrossRefPubMedPubMedCentral

52.

Yeger H, Baumal R, Harason P, Phillips MJ. Lectin histochemistry of Wilms’ tumor. Comparison with normal adult and fetal kidney. Am J Clin Pathol. 1987;88(3):278–85. https://doi.org/10.1093/ajcp/88.3.278.CrossRefPubMed

53.

Aldrink JH, Heaton TE, Dasgupta R, et al. Update on Wilms tumor. J Pediatr Surg. 2019;54(3):390–7. https://doi.org/10.1016/j.jpedsurg.2018.09.005.CrossRefPubMed

54.

Miller-Hodges E. Clinical aspects of WT1 and the kidney. Methods Mol Biol. 2016;1467:15–21. https://doi.org/10.1007/978-1-4939-4023-3_2.CrossRefPubMed

55.

Kreidberg JA, Sariola H, Loring JM, et al. WT-1 is required for early kidney development. Cell. 1993;74(4):679–91. https://doi.org/10.1016/0092-8674(93)90515-r.CrossRefPubMed

56.

Sun LZ, Wang HY, Li M, et al. Clinical and pathological features and mutational types of WT1 mutation-associated nephropathy. Zhonghua Er Ke Za Zhi. 2018;56(10):769–74. https://doi.org/10.3760/cma.j.issn.0578-1310.2018.10.010.CrossRefPubMed

57.

Hastie ND. Wilms’ tumour 1 (WT1) in development, homeostasis and disease. Development. 2017;144(16):2862–72. https://doi.org/10.1242/dev.153163.CrossRefPubMed

58.

Shankland SJ, Pippin JW, Duffield JS. Progenitor cells and podocyte regeneration. Semin Nephrol. 2014;34(4):418–28. https://doi.org/10.1016/j.semnephrol.2014.06.008.CrossRefPubMedPubMedCentral

59.

Kabgani N, Grigoleit T, Schulte K, et al. Primary cultures of glomerular parietal epithelial cells or podocytes with proven origin. PLoS ONE. 2012;7(4): e34907. https://doi.org/10.1371/journal.pone.0034907.CrossRefPubMedPubMedCentral

60.

Kim MK, McGarry TJ, Broin PO, Flatow JM, Golden AA, Licht JD. An integrated genome screen identifies the Wnt signaling pathway as a major target of WT1. Proc Natl Acad Sci USA. 2009;106(27):11154–9. https://doi.org/10.1073/pnas.0901591106.CrossRefPubMedPubMedCentral

61.

Gebeshuber CA, Kornauth C, Dong L, et al. Focal segmental glomerulosclerosis is induced by microRNA-193a and its downregulation of WT1. Nat Med. 2013;19(4):481–7. https://doi.org/10.1038/nm.3142.CrossRefPubMed

62.

Kumar V, Vashistha H, Lan X, et al. Role of apolipoprotein L1 in human parietal epithelial cell transition. Am J Pathol. 2018;188(11):2508–28. https://doi.org/10.1016/j.ajpath.2018.07.025.CrossRefPubMedPubMedCentral

63.

Spagnuolo R, Corada M, Orsenigo F, et al. Gas1 is induced by VE-cadherin and vascular endothelial growth factor and inhibits endothelial cell apoptosis. Blood. 2004;103(8):3005–12. https://doi.org/10.1182/blood-2003-07-2459.CrossRefPubMed

64.

Kann M, Bae E, Lenz MO, et al. WT1 targets Gas1 to maintain nephron progenitor cells by modulating FGF signals. Development. 2015;142(7):1254–66. https://doi.org/10.1242/dev.119735.CrossRefPubMedPubMedCentral

65.

Luna-Antonio BI, Rodriguez-Muñoz R, Namorado-Tonix C, Vergara P, Segovia J, Reyes JL. Gas1 expression in parietal cells of Bowman’s capsule in experimental diabetic nephropathy. Histochem Cell Biol. 2017;148(1):33–47. https://doi.org/10.1007/s00418-017-1550-z.CrossRefPubMed

66.

Kim MS, Yoon SK, Bollig F, et al. A novel Wilms tumor 1 (WT1) target gene negatively regulates the WNT signaling pathway. J Biol Chem. 2010;285(19):14585–93. https://doi.org/10.1074/jbc.M109.094334.CrossRefPubMedPubMedCentral

67.

Zhou L, Li Y, He W, et al. Mutual antagonism of Wilms’ tumor 1 and β-catenin dictates podocyte health and disease. J Am Soc Nephrol. 2015;26(3):677–91. https://doi.org/10.1681/asn.2013101067.CrossRefPubMed

68.

Asfahani RI, Tahoun MM, Miller-Hodges EV, et al. Activation of podocyte notch mediates early Wt1 glomerulopathy. Kidney Int. 2018;93(4):903–20. https://doi.org/10.1016/j.kint.2017.11.014.CrossRefPubMedPubMedCentral

69.

Romoli S, Angelotti ML, Antonelli G, et al. CXCL12 blockade preferentially regenerates lost podocytes in cortical nephrons by targeting an intrinsic podocyte-progenitor feedback mechanism. Kidney Int. 2018;94(6):1111–26. https://doi.org/10.1016/j.kint.2018.08.013.CrossRefPubMedPubMedCentral

70.

Rizzo P, Novelli R, Rota C, et al. The role of angiotensin II in parietal epithelial cell proliferation and crescent formation in glomerular diseases. Am J Pathol. 2017;187(11):2441–50. https://doi.org/10.1016/j.ajpath.2017.07.004.CrossRefPubMed

71.

Wang Y, Borchert ML, DeLuca HF. Identification of the vitamin D receptor in various cells of the mouse kidney. Kidney Int. 2012;81(10):993–1001. https://doi.org/10.1038/ki.2011.463.CrossRefPubMedPubMedCentral

72.

Lasagni L, Ballerini L, Angelotti ML, et al. Notch activation differentially regulates renal progenitors proliferation and differentiation toward the podocyte lineage in glomerular disorders. Stem Cells. 2010;28(9):1674–85. https://doi.org/10.1002/stem.492.CrossRefPubMedPubMedCentral

73.

Yadav A, Vallabu S, Kumar D, et al. HIVAN phenotype: consequence of epithelial mesenchymal transdifferentiation. Am J Physiol Renal Physiol. 2010;298(3):F734-744. https://doi.org/10.1152/ajprenal.00415.2009.CrossRefPubMed

74.

Massa F, Schedl A. Awakening the Bowman: inhibition of CXCL12 signaling activates parietal epithelial cells. Kidney Int. 2018;94(6):1042–4. https://doi.org/10.1016/j.kint.2018.09.011.CrossRefPubMed

75.

Flamant M, Bollée G, Hénique C, Tharaux PL. Epidermal growth factor: a new therapeutic target in glomerular disease. Nephrol Dial Transpl. 2012;27(4):1297–304. https://doi.org/10.1093/ndt/gfs030.CrossRef

76.

Bollée G, Flamant M, Schordan S, et al. Epidermal growth factor receptor promotes glomerular injury and renal failure in rapidly progressive crescentic glomerulonephritis. Nat Med. 2011;17(10):1242–50. https://doi.org/10.1038/nm.2491.CrossRefPubMedPubMedCentral

77.

Kurayama R, Ito N, Nishibori Y, et al. Role of amino acid transporter LAT2 in the activation of mTORC1 pathway and the pathogenesis of crescentic glomerulonephritis. Lab Invest. 2011;91(7):992–1006. https://doi.org/10.1038/labinvest.2011.43.CrossRefPubMed

Title: The recruitment mechanisms and potential therapeutic targets of podocytes from parietal epithelial cells
Authors: Lihua Ni
Cheng Yuan
Xiaoyan Wu
Publication date: 01-12-2021
Publisher: BioMed Central
Published in: Journal of Translational Medicine / Issue 1/2021
Electronic ISSN: 1479-5876
DOI: https://doi.org/10.1186/s12967-021-03101-z

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2021

Fe3O4 magnetic nanoparticle-enhanced radiotherapy for lung adenocarcinoma via delivery of siBIRC5 and AS-ODN

Centenarian longevity had inverse relationships with nutritional status and abdominal obesity and positive relationships with sex hormones and bone turnover in the oldest females

Integrated analysis of lncRNA, miRNA and mRNA profiles reveals potential lncRNA functions during early HIV infection

Extracellular vesicles carrying miRNA-181b-5p affects the malignant progression of acute lymphoblastic leukemia

Pharmacological targeting of Tripartite Motif Containing 24 for the treatment of glioblastoma

Long non-coding RNA NORAD promotes pancreatic cancer stem cell proliferation and self-renewal by blocking microRNA-202-5p-mediated ANP32E inhibition

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage